Kiora Pharmaceuticals Stock Analysis

KPRX Stock  USD 3.18  0.03  0.95%   
Kiora Pharmaceuticals is overvalued with Real Value of 2.74 and Target Price of 11.0. The main objective of Kiora Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Kiora Pharmaceuticals is worth, separate from its market price. There are two main types of Kiora Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Kiora Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Kiora Pharmaceuticals is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Kiora Stock trading window is adjusted to America/New York timezone.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

Kiora Stock Analysis Notes

About 46.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.41. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kiora Pharmaceuticals recorded a loss per share of 4.26. The entity last dividend was issued on the 30th of August 2019. The firm had 1:9 split on the 11th of June 2024. Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To find out more about Kiora Pharmaceuticals contact Brian Strem at 858 224 9600 or learn more at https://www.kiorapharma.com.

Kiora Pharmaceuticals Investment Alerts

Kiora Pharmaceuticals had very high historical volatility over the last 90 days
Latest headline from news.google.com: Kiora Pharmaceuticals Upgraded to Strong Buy Heres What You Should Know - MSN

Kiora Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Kiora Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
28th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Kiora Largest EPS Surprises

Earnings surprises can significantly impact Kiora Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-03-25
2023-12-31-0.42-0.47-0.0511 
2025-05-08
2025-03-31-0.77-0.520.2532 
2023-08-08
2023-06-30-1.07-0.790.2826 
View All Earnings Estimates

Kiora Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Kiora Pharmaceuticals' ESG score is a quantitative measure that evaluates Kiora Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Kiora Pharmaceuticals' operations that may have significant financial implications and affect Kiora Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Kiora Stock Institutional Investors

Shares
Sbi Securities Co Ltd2025-03-31
256
Blackrock Inc2025-03-31
58.0
Goss Wealth Management Llc2025-03-31
22.0
Bank Of America Corp2025-03-31
20.0
Ubs Group Ag2025-03-31
2.0
Advisor Group Holdings, Inc.2025-03-31
2.0
Activest Wealth Management2025-03-31
2.0
Susquehanna International Group, Llp2024-12-31
0.0
U.s. Bancorp2025-03-31
0.0
Aigh Capital Management, Llc2025-03-31
253.6 K
Rosalind Advisors, Inc.2025-03-31
250.1 K
Note, although Kiora Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kiora Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.68 M.

Kiora Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets 0.12  0.13 
Return On Capital Employed 0.15  0.14 
Return On Assets 0.10  0.10 
Return On Equity 0.14  0.13 

Management Efficiency

Kiora Pharmaceuticals has return on total asset (ROA) of (0.1583) % which means that it has lost $0.1583 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4113) %, meaning that it created substantial loss on money invested by shareholders. Kiora Pharmaceuticals' management efficiency ratios could be used to measure how well Kiora Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kiora Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.10 in 2025, whereas Return On Capital Employed is likely to drop 0.14 in 2025. At this time, Kiora Pharmaceuticals' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2.1 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 6.2 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 6.65  6.98 
Tangible Book Value Per Share 4.92  5.17 
Enterprise Value Over EBITDA 1.57  1.65 
Price Book Value Ratio 0.50  0.52 
Enterprise Value Multiple 1.57  1.65 
Price Fair Value 0.50  0.52 
Enterprise ValueM8.6 M
The strategic initiatives led by Kiora Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Operating Margin
(484.21)
Beta
(0.68)
Return On Assets
(0.16)
Return On Equity
(0.41)

Technical Drivers

As of the 21st of July, Kiora Pharmaceuticals secures the Risk Adjusted Performance of 0.0672, downside deviation of 4.1, and Mean Deviation of 2.93. Kiora Pharmaceuticals technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.

Kiora Pharmaceuticals Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Kiora Pharmaceuticals for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Kiora Pharmaceuticals short-term fluctuations and highlight longer-term trends or cycles.

Kiora Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kiora Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kiora Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kiora Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Brian Strem over a month ago
Acquisition by Brian Strem of 18750 shares of Kiora Pharmaceuticals subject to Rule 16b-3
 
Daniels Eric Joseph over a month ago
Acquisition by Daniels Eric Joseph of 62500 shares of Kiora Pharmaceuticals subject to Rule 16b-3
 
Brian Strem over two months ago
Acquisition by Brian Strem of 18750 shares of Kiora Pharmaceuticals subject to Rule 16b-3
 
Walters-hoffert Lisa over three months ago
Acquisition by Walters-hoffert Lisa of 20000 shares of Kiora Pharmaceuticals at 2.93 subject to Rule 16b-3
 
Gayron Kenneth L over three months ago
Acquisition by Gayron Kenneth L of 8000 shares of Kiora Pharmaceuticals at 3.83 subject to Rule 16b-3
 
Melissa Tosca over three months ago
Acquisition by Melissa Tosca of 2500 shares of Kiora Pharmaceuticals subject to Rule 16b-3
 
Shapiro Aron over six months ago
Acquisition by Shapiro Aron of 3000 shares of Kiora Pharmaceuticals at 3.6 subject to Rule 16b-3
 
Shapiro Aron over six months ago
Acquisition by Shapiro Aron of 5000 shares of Kiora Pharmaceuticals at 0.5677 subject to Rule 16b-3
 
Stengone Carmine N. over six months ago
Acquisition by Stengone Carmine N. of 1250 shares of Kiora Pharmaceuticals at 3.68 subject to Rule 16b-3
 
Shapiro Aron over six months ago
Acquisition by Shapiro Aron of 3000 shares of Kiora Pharmaceuticals at 3.6 subject to Rule 16b-3
 
Hollander David over six months ago
Acquisition by Hollander David of 1778 shares of Kiora Pharmaceuticals at 4.35 subject to Rule 16b-3
 
Tyle Praveen over six months ago
Acquisition by Tyle Praveen of 5000 shares of Kiora Pharmaceuticals at 3.96 subject to Rule 16b-3

Kiora Pharmaceuticals Outstanding Bonds

Kiora Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kiora Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kiora bonds can be classified according to their maturity, which is the date when Kiora Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Kiora Pharmaceuticals Predictive Daily Indicators

Kiora Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kiora Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Kiora Pharmaceuticals Forecast Models

Kiora Pharmaceuticals' time-series forecasting models are one of many Kiora Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kiora Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Kiora Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kiora Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kiora shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Kiora Pharmaceuticals. By using and applying Kiora Stock analysis, traders can create a robust methodology for identifying Kiora entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.41  0.43 
Operating Profit Margin 0.32  0.34 
Net Profit Margin 0.26  0.27 
Gross Profit Margin 0.90  0.94 

Current Kiora Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kiora analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kiora analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
11.0Buy2Odds
Kiora Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Kiora analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Kiora stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kiora Pharmaceuticals, talking to its executives and customers, or listening to Kiora conference calls.
Kiora Analyst Advice Details

Kiora Stock Analysis Indicators

Kiora Pharmaceuticals stock analysis indicators help investors evaluate how Kiora Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kiora Pharmaceuticals shares will generate the highest return on investment. By understating and applying Kiora Pharmaceuticals stock analysis, traders can identify Kiora Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow2.5 M
Common Stock Shares Outstanding4.1 M
Total Stockholder Equity25.8 M
Total Cashflows From Investing Activities-22.7 M
Tax Provision2.1 M
Property Plant And Equipment Net62.4 K
Cash And Short Term Investments26.8 M
Cash3.8 M
Accounts Payable415.6 K
Net Debt-3.7 M
50 Day M A3.0784
Total Current LiabilitiesM
Other Operating Expenses11.5 M
Non Current Assets Total6.8 M
Forward Price Earnings2.4102
Non Currrent Assets Other29 K
Stock Based Compensation656.6 K

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.